Last updated: February 15, 2026
What is Lestaurtinib?
Lestaurtinib is a kinase inhibitor primarily targeting Janus kinase 2 (JAK2) and FLT3 mutations. Its development focuses on treating hematologic malignancies, including acute myeloid leukemia (AML) with FLT3 mutations. It was originally developed by Teva Pharmaceuticals and later acquired or licensed by other firms for further clinical development.
What is the current development status of Lestaurtinib?
Lestaurtinib has undergone multiple clinical trials, primarily as a treatment for AML. As of 2022, the drug remains in the experimental phase, with no approved indications. The most recent notable trial was a Phase 2 study evaluating its efficacy combined with chemotherapy in AML patients with FLT3 mutations.
Clinical Trial Data
| Trial Phase |
Primary Endpoint |
Enrollment |
Outcome Summary |
| Phase 2 (2018) |
Complete remission rate |
45 patients |
Partial response observed; no significant improvement over standard therapy |
| Ongoing |
Safety & tolerability |
Unknown |
No recent updates, trial status unconfirmed as of 2022 |
Regulatory Status
Lestaurtinib has not secured regulatory approval from agencies such as the FDA or EMA. Prior Investigational New Drug (IND) applications have been withdrawn or expired, owing to lack of demonstrated efficacy or strategic shifts in development priorities.
What is the market potential for Lestaurtinib?
AML is a multi-billion dollar market projected to grow at a CAGR of approximately 8% through 2027. FLT3-mutated AML constitutes roughly 20-25% of cases, representing a significant subset for targeted therapies.
Key Market Data
- Global AML drug market (2022): $2.8 billion (Source: MarketWatch [1])
- Expected CAGR (2022-2027): 8% (Source: Grand View Research [2])
- FLT3-mutated AML prevalence: 20-25% of AML cases (Source: Leukemia & Lymphoma Society [3])
- Existing FLT3 inhibitors: Midostaurin (approved), Gilteritinib (approved), quizartinib (Phase 3)
Competitive Landscape
| Drug |
Status |
Approved Indications |
Market Share (2022) |
Notes |
| Gilteritinib |
Approved |
Relapsed/refractory FLT3 AML |
>50% of FLT3 market |
Market leader |
| Midostaurin |
Approved |
Newly diagnosed FLT3 AML |
30% of FLT3 market |
Off-label use in relapsed cases |
| Quizartinib |
Phase 3 |
Relapsed FLT3 AML |
- |
Pending approval |
Lestaurtinib faces obstacles, including limited efficacy demonstrated in phase 2 trials and competition from already approved drugs with proven benefit profiles.
How does Lestaurtinib compare to existing therapies?
Compared to gilteritinib and midostaurin, Lestaurtinib lacks strong clinical evidence of superior efficacy. Its side effect profile also appears comparable but less favorable, based on available trial data.
- Efficacy: Gilteritinib shows overall response rates up to 50% in relapsed/refractory FLT3-ITD AML. Lestaurtinib's response rate was significantly lower in Phase 2 trials.
- Safety profile: Similar adverse events such as cytopenias, gastrointestinal symptoms, and liver enzyme elevations. No significant safety advantages observed.
- Regulatory confidence: Approved FLT3 inhibitors have demonstrated consistent clinical benefit, contributing to their market dominance.
What is the outlook for Lestaurtinib?
Given the limited efficacy data, lack of recent clinical progress, and strong competition, the outlook for Lestaurtinib remains uncertain. It would require new evidence of clinical benefit or novel combinatorial strategies to regain relevance.
Market projections reflect the dominance of existing FLT3 inhibitors; the global AML drug market is projected to continue expanding, but new entrants need to demonstrate clear advantages to displace or complement current standards.
Key Takeaways
- Lestaurtinib's development has stagnated, with no recent clinical trials or regulatory applications.
- The competitive landscape favors drugs with proven clinical efficacy, such as gilteritinib.
- Market potential exists within FLT3-mutated AML, but Lestaurtinib's prospects are limited without significant efficacy improvements.
- The AML market continues to grow, driven by unmet needs and targeted therapies, but Lestaurtinib is unlikely to capitalize without substantial new data.
- Strategic partners or new formulations could be necessary to revive its development.
FAQs
1. Is Lestaurtinib currently in clinical trials?
No publicly known active clinical trials for Lestaurtinib are ongoing as of 2022.
2. Has Lestaurtinib received regulatory approval?
No, the drug remains investigational with no approvals from major regulatory agencies.
3. How does the efficacy of Lestaurtinib compare to approved FLT3 inhibitors?
It has demonstrated lower response rates in trials compared to gilteritinib and midostaurin.
4. What are the main competitors to Lestaurtinib in the AML market?
Gilteritinib, midostaurin, and quizartinib hold primary market share in FLT3-mutant AML.
5. Could Lestaurtinib find a niche in AML treatment?
Possible if novel combinations or delivery methods show improved efficacy; current data do not support this.
Sources
[1] MarketWatch, "AML Therapeutics Market Size," 2022.
[2] Grand View Research, "AML Market CAGR," 2022.
[3] Leukemia & Lymphoma Society, "FLT3 Mutations in AML," 2021.
